<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 21-year-old woman with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> underwent allogeneic bone marrow transplantation from an HLA-identical sibling donor </plain></SENT>
<SENT sid="1" pm="."><plain>The patient also had <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B and the donor was an HBV carrier </plain></SENT>
<SENT sid="2" pm="."><plain>To decrease HBV and improve hepatic dysfunction before BMT, the patient had received lamivudine for 6 months </plain></SENT>
<SENT sid="3" pm="."><plain>After marrow transfusion, administration of lamivudine was continued to inhibit replication of donor-derived HBV </plain></SENT>
<SENT sid="4" pm="."><plain>The patient showed hematological engraftment on day 13 without any serious <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Eight months after BMT, she is now alive and well without <z:hpo ids='HP_0011010'>chronic</z:hpo> liver GVHD or reactivation of <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B </plain></SENT>
<SENT sid="6" pm="."><plain>HBV-DNA was not detected in the patient's serum </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of lamivudine to a BMT recipient with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B may be a safe and promising way to prevent fatal <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> in the setting of allogeneic BMT, even in the event of BMT from an HBV-positive donor </plain></SENT>
</text></document>